DRTS — Alpha Tau Medical Income Statement
0.000.00%
Last trade - 00:00- $748.96m
- $682.19m
Annual income statement for Alpha Tau Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13.8 | 32.1 | 35.7 | 36 | 42.3 |
| Operating Profit | -13.8 | -32.1 | -35.7 | -36 | -42.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.3 | -33.7 | -29.1 | -31.7 | -42.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -27.3 | -33.8 | -29.2 | -31.8 | -42.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.3 | -33.8 | -29.2 | -31.8 | -42.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.3 | -33.8 | -29.2 | -31.8 | -42.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.398 | -0.531 | -0.42 | -0.454 | -0.529 |
| Dividends per Share |